GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...
AstraZeneca breached the UK pharmaceutical industry's code of practice after a website claim incorrectly stated that all ...
GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...
The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...
For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback